Hexarelin
Hexarelin (Examorelin)
Hexarelin (Examorelin) is a synthetic hexapeptide GHRP and the most potent GH secretagogue in the GHRP class. It produces the largest GH pulses of any GHRP at equivalent doses, but also the most significant receptor desensitisation with chronic use and meaningful cortisol and prolactin elevation. Uniquely among GHRPs, Hexarelin has direct cardioprotective effects via cardiac GHSR-1a and CD36 receptor activation — independent of its GH-releasing activity.
Mechanism of Action
Hexarelin activates GHSR-1a with exceptionally high potency, producing GH pulse amplitudes that exceed GHRP-2 and GHRP-6 at equivalent doses. It also acts at the hypothalamic level to suppress somatostatin, contributing to its superior pulse magnitude.
Uniquely, Hexarelin has been shown to exert direct cardioprotective effects through two cardiac receptor pathways: GHSR-1a activation in cardiomyocytes promotes cell survival after ischaemia, and CD36 receptor activation (a scavenger receptor) reduces cardiac lipid accumulation. These effects occur independently of GH release and have been confirmed in cardiomyopathy models.
The most significant limitation of Hexarelin is rapid receptor desensitisation. GHSR-1a downregulates after 4–6 weeks of continuous use, reducing GH pulse amplitude progressively. This mandates cycle protocols with adequate off-periods to restore receptor sensitivity.
Research Evidence
Hexarelin has Phase 1/2 clinical data including cardiac research. Its direct cardioprotective mechanism is one of the most distinctive features of any GHRP. Research also supports its use in GH deficiency testing.
Hexarelin Exerts Cardioprotective Effects Independent of GH Release
Hexarelin reduced infarct size, improved cardiac function, and decreased cardiomyocyte apoptosis in ischaemia-reperfusion models even in GH-deficient animals — confirming direct cardiac receptor-mediated protection independent of the GH axis.
Hexarelin Phase 2: Cardiac Function in GH-Deficient Adults
Hexarelin administration to GH-deficient adults produced significant improvements in cardiac function parameters (ejection fraction, cardiac output) beyond what GH replacement alone achieved, supporting a direct cardiac mechanism.
Typical Research Protocol
Hexarelin's potency means lower doses may be effective. Strict cycle protocols (4–6 weeks on, 4+ weeks off) are necessary to prevent progressive receptor desensitisation. For GH optimisation, CJC-1295 + Ipamorelin is generally preferred for long-term use due to better sustained response.
Safety Profile
Reported Side Effects
- Cortisol elevation (significant at higher doses)
- Prolactin increase
- Rapid receptor desensitisation
- Water retention
- Appetite increase
- Fatigue
Contraindications
- Active malignancy
- Cardiac conditions (paradoxical concern despite cardiac data — consult cardiologist)
- Pregnancy
- Epilepsy
- Hypothyroidism
Common Research Stacks
Frequently Asked Questions
Is Hexarelin the most powerful GHRP?
Yes — among the classic GHRPs (GHRP-2, GHRP-6, Ipamorelin, Hexarelin), Hexarelin produces the largest GH pulses at equivalent doses due to its high GHSR-1a potency and dual hypothalamic-pituitary action. However, this potency comes with the greatest receptor desensitisation, strongest cortisol/prolactin co-stimulation, and least forgiving side effect profile.
What makes Hexarelin unique from other GHRPs?
Hexarelin's direct cardioprotective effects via CD36 and cardiac GHSR-1a receptors are unique in the GHRP class. It protects against myocardial ischaemia-reperfusion injury independently of GH release — a property not shared by GHRP-2, GHRP-6, or Ipamorelin. This cardiac mechanism has generated research interest for heart failure and cardiac recovery applications beyond its GH secretagogue role.
How quickly does Hexarelin cause receptor desensitisation?
Measurable GHSR-1a desensitisation typically begins within 2–4 weeks of continuous twice-daily use, with GH pulse amplitude declining progressively. After 6–8 weeks of continuous use, GH responses may be 50–70% lower than at baseline. Off periods of 4–8 weeks are required to restore receptor sensitivity. This desensitisation is more pronounced than with Ipamorelin.
Can Hexarelin be used for cardiac conditions?
The cardiac research on Hexarelin is genuinely compelling — Phase 2 data showed improvements in cardiac function beyond GH replacement alone in GH-deficient adults with cardiac compromise. However, using unregulated research-grade Hexarelin for cardiac conditions outside a clinical trial is not recommended. The cardiac benefits need clinical trial validation before medical use. Discuss with a cardiologist specialising in peptide research if considering cardiac applications.
What is the right dose to minimise cortisol?
At doses of 100 mcg, Hexarelin's cortisol stimulation is modest. At 200 mcg, cortisol elevation becomes meaningful. At ≥300 mcg, ACTH/cortisol co-stimulation is significant. The typical research approach caps Hexarelin at 100–200 mcg twice daily. Given its superior potency, 100 mcg Hexarelin may produce comparable GH response to 200 mcg GHRP-2, making dose discipline important.
Key Research References
- Torsello A et al. (2002). Hexarelin and the cardiovascular system. Eur J Pharmacol.
- Ghigo E et al. (1997). Hexarelin and cardiac function in GH deficiency. J Clin Endocrinol Metab.
Explore more Growth Hormone research compounds
Browse Growth Hormone →